Evolus, Inc. (EOLS): Price and Financial Metrics
GET POWR RATINGS... FREE!
EOLS POWR Grades
- EOLS scores best on the Growth dimension, with a Growth rank ahead of 82.12% of US stocks.
- The strongest trend for EOLS is in Growth, which has been heading up over the past 177 days.
- EOLS ranks lowest in Stability; there it ranks in the 18th percentile.
EOLS Stock Summary
- EVOLUS INC's capital turnover -- a measure of revenue relative to shareholder's equity -- is better than 95.19% of US listed stocks.
- Equity multiplier, or assets relative to shareholders' equity, comes in at 4.96 for EVOLUS INC; that's greater than it is for 79.74% of US stocks.
- As for revenue growth, note that EOLS's revenue has grown 49.1% over the past 12 months; that beats the revenue growth of 84.12% of US companies in our set.
- Stocks that are quantitatively similar to EOLS, based on their financial statements, market capitalization, and price volatility, are PLCE, KD, TREE, RSI, and BOXL.
- Visit EOLS's SEC page to see the company's official filings. To visit the company's web site, go to www.evolus.com.
EOLS Valuation Summary
- In comparison to the median Healthcare stock, EOLS's EV/EBIT ratio is 215.15% lower, now standing at -7.6.
- EOLS's EV/EBIT ratio has moved up 33.2 over the prior 62 months.
Below are key valuation metrics over time for EOLS.
| Stock | Date | P/S | P/B | P/E | EV/EBIT |
|---|---|---|---|---|---|
| EOLS | 2023-03-24 | 3.2 | 25.7 | -6.4 | -7.6 |
| EOLS | 2023-03-23 | 3.1 | 25.2 | -6.3 | -7.5 |
| EOLS | 2023-03-22 | 3.1 | 25.3 | -6.3 | -7.5 |
| EOLS | 2023-03-21 | 3.2 | 25.7 | -6.4 | -7.6 |
| EOLS | 2023-03-20 | 3.2 | 25.6 | -6.4 | -7.6 |
| EOLS | 2023-03-17 | 3.2 | 25.5 | -6.3 | -7.6 |
EOLS's Quality Factors
The “Quality” component of the POWR Ratings focuses on 31 different factors of a companies fundamentals and operational strength. Here are some key insights as we drill into the specifics of these quality attributes.- EOLS has a Quality Grade of C, ranking ahead of 44.26% of graded US stocks.
- EOLS's asset turnover comes in at 0.373 -- ranking 125th of 681 Pharmaceutical Products stocks.
- 500 - Internal server error
The table below shows EOLS's key quality metrics over time.
| Period | Asset Turnover | Gross Margin | ROIC |
|---|---|---|---|
| 2021-06-30 | 0.373 | 0.630 | -3.772 |
| 2021-03-31 | 0.300 | 0.674 | -1.580 |
| 2020-12-31 | 0.271 | 0.676 | -1.214 |
| 2020-09-30 | 0.256 | 0.735 | -0.356 |
| 2020-06-30 | 0.245 | 0.734 | -0.491 |
| 2020-03-31 | 0.216 | 0.731 | -0.603 |
EOLS Price Target
For more insight on analysts targets of EOLS, see our EOLS price target page. And for a list of of all stocks sorted by upside potential based on analyst target price, see our Top Price Target page.
| Average Price Target | $17.14 | Average Broker Recommendation | 1.57 (Moderate Buy) |
EOLS Stock Price Chart Interactive Chart >
EOLS Price/Volume Stats
| Current price | $8.27 | 52-week high | $14.34 |
| Prev. close | $8.34 | 52-week low | $6.51 |
| Day low | $8.27 | Volume | 25,775 |
| Day high | $8.48 | Avg. volume | 528,956 |
| 50-day MA | $9.19 | Dividend yield | N/A |
| 200-day MA | $9.30 | Market Cap | 466.53M |
Evolus, Inc. (EOLS) Company Bio
Evolus, Inc. provides medical aesthetic products for physicians and their patients in the United States. It offers DWP-450, an injectable 900 kilodalton botulinum toxin type A complex designed to address the needs of the facial aesthetics market. The company was founded in 2012 and is based in Irvine, California.
Latest EOLS News From Around the Web
Below are the latest news stories about EVOLUS INC that investors may wish to consider to help them evaluate EOLS as an investment opportunity.
Evolus, Inc. (NASDAQ:EOLS) Q4 2022 Earnings Call TranscriptEvolus, Inc. (NASDAQ:EOLS) Q4 2022 Earnings Call Transcript March 8, 2023 Operator: Greetings, and welcome to the Evolus Fourth Quarter 2022 Earnings Conference Call. At this time, all participants are in a listen-only mode. A brief question-and-answer session will follow the formal presentation. As a reminder, this conference is being recorded. It is now my […] |
Q4 2022 Evolus Inc Earnings CallQ4 2022 Evolus Inc Earnings Call |
Evolus, Inc. (EOLS) Reports Q4 Loss, Tops Revenue EstimatesEvolus, Inc. (EOLS) delivered earnings and revenue surprises of -14.29% and 0.39%, respectively, for the quarter ended December 2022. Do the numbers hold clues to what lies ahead for the stock? |
Evolus Reports Fourth Quarter and Full Year 2022 Results and Provides Business UpdateNEWPORT BEACH, Calif., March 08, 2023--Evolus reports financial results for the fourth quarter and full year ended December 31, 2022 and provides a business update |
Evolus to Participate in the Barclays Global Healthcare ConferenceNEWPORT BEACH, Calif., February 28, 2023--Evolus announces that members of its management team will be participating in the Barclays Global Healthcare Conference in Miami Beach, Florida. |
EOLS Price Returns
| 1-mo | -8.82% |
| 3-mo | 10.12% |
| 6-mo | 2.73% |
| 1-year | -25.23% |
| 3-year | 104.70% |
| 5-year | -8.42% |
| YTD | 10.12% |
| 2022 | 15.36% |
| 2021 | 93.75% |
| 2020 | -72.39% |
| 2019 | 2.27% |
| 2018 | N/A |
Continue Researching EOLS
Want to see what other sources are saying about Evolus Inc's financials and stock price? Try the links below:Evolus Inc (EOLS) Stock Price | Nasdaq
Evolus Inc (EOLS) Stock Quote, History and News - Yahoo Finance
Evolus Inc (EOLS) Stock Price and Basic Information | MarketWatch
Loading social stream, please wait...